Abstract Details

Title Electronic Assessment of Quality of Life in Glioma Patients Using the EORTC-QLQ-C30/ EORTC-BN20 and the PROMIS System in Clinical Practice

Topic Neuro-oncology

Presentation(s) P3 - Poster Session 3 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-008

Objective

We aim to assess feasibility of computer adaptations of the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire in the clinical setting and compare it with outcomes of the EORTC- QLQ-C30 and EORTC-BN20 questionnaires.

Background Glioblastoma (GBM) is the most aggressive malignant primary brain tumor causing high levels of distress and morbidity. Electronic assessment of quality of life (HRQoL) with standardized methods is of importance.

Design/Methods

Newly diagnosed patients with GBM were enrolled to assess feasibility. The PROMIS modules were selected to reflect the HRQoL domains assessed in the EORTC- QLQ-C30 and EORTC-BN20 questionnaires. PROMIS modules selected included anxiety, depression, fatigue, physical function, sleep disturbance, sleep-related impairment, social satisfaction role, applied cognitive ability and global health.

Results

31 patients completed the survey prior to or within 14 days of start of radiation, 12 patients completed a survey outside of the radiation window, and a total of 60 completed surveys were obtained between both patient groups. Descriptive analysis was performed. The median times to complete the EORTC-QLQ-C30 and the EORTC-BN20 surveys were 4.77 (range=2.05-18.6) and 2.63 (range=1.17- 24.83) minutes respectively. For the PROMIS instruments except global health, the median times to complete different modules ranged from 0.6- 1 minute (range= 0.15-7.77). For global health, the median time was 2.35 minutes (range= 1.02-21.12). Average time to complete all PROMIS questions was 8.65 minutes (range=3.32-66.01).

Conclusions Real-time prospective assessment without integration into the clinic work-flow is a limiting factor of the PROMIS/EORTC. Online assessment from home was challenging for patients with less social support, low computer literacy and the burden of disease also limits quantity of responses. Electronic assessment of QoL is preferred, but not all patients were able to participate.

Authors/Disclosures
Dennis Josh Mohn, DO (Henry Ford Health) PRESENTER	Dr. Mohn has nothing to disclose.
Tobias Walbert, MD, PhD, FAAN (Henry Ford Hospital Detroit)	Dr. Walbert has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Walbert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus Therapeutics. Dr. Walbert has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics . Dr. Walbert has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Springworks Therapeutics . Dr. Walbert has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion .
Lonni Schultz, PhD (Henry Ford Hospital)	Dr. Schultz has nothing to disclose.
James Snyder, DO	The institution of Dr. Snyder has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Diagnostics. The institution of Dr. Snyder has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Premier Applied Sciences. The institution of Dr. Snyder has received research support from Vizilitics inc.

��ɫ��

��ɫ��